GLAXF Quote, Financials, Valuation and Earnings

Autolus Therapeutics Plc has a net margin of 25.09% compared to GSK Plc's net margin of -373.3%. GSK Plc's return on equity of 42.84% beat Autolus Therapeutics Plc's return on equity of -59.51%.

GSK Plc has a consensus price target of --, signalling downside risk potential of --. On the other hand Autolus Therapeutics Plc has an analysts' consensus of $9.52 which suggests that it could grow by 539.08%. Given that Autolus Therapeutics Plc has higher upside potential than GSK Plc, analysts believe Autolus Therapeutics Plc is more attractive than GSK Plc.

GSK Plc has a beta of 0.211, which suggesting that the stock is 78.943% less volatile than S&P 500. In comparison Autolus Therapeutics Plc has a beta of 2.013, suggesting its more volatile than the S&P 500 by 101.348%.

GSK Plc has a quarterly dividend of $0.21 per share corresponding to a yield of 3.36%. Autolus Therapeutics Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GSK Plc pays 96.58% of its earnings as a dividend. Autolus Therapeutics Plc pays out -- of its earnings as a dividend. GSK Plc's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

GSK Plc quarterly revenues are $11.5B, which are larger than Autolus Therapeutics Plc quarterly revenues of $21.1M. GSK Plc's net income of $2.9B is higher than Autolus Therapeutics Plc's net income of -$78.6M. Notably, GSK Plc's price-to-earnings ratio is 14.26x while Autolus Therapeutics Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GSK Plc is 2.45x versus 7.74x for Autolus Therapeutics Plc. Usually stocks with elevated PS ratios are considered overvalued.

Biodexa Pharmaceuticals Plc has a net margin of 25.09% compared to GSK Plc's net margin of --. GSK Plc's return on equity of 42.84% beat Biodexa Pharmaceuticals Plc's return on equity of -160.77%.

GSK Plc has a consensus price target of --, signalling downside risk potential of --. On the other hand Biodexa Pharmaceuticals Plc has an analysts' consensus of $17.94 which suggests that it could grow by 4269.81%. Given that Biodexa Pharmaceuticals Plc has higher upside potential than GSK Plc, analysts believe Biodexa Pharmaceuticals Plc is more attractive than GSK Plc.

GSK Plc has a beta of 0.211, which suggesting that the stock is 78.943% less volatile than S&P 500. In comparison Biodexa Pharmaceuticals Plc has a beta of 0.955, suggesting its less volatile than the S&P 500 by 4.507%.

GSK Plc has a quarterly dividend of $0.21 per share corresponding to a yield of 3.36%. Biodexa Pharmaceuticals Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GSK Plc pays 96.58% of its earnings as a dividend. Biodexa Pharmaceuticals Plc pays out -- of its earnings as a dividend. GSK Plc's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

GSK Plc quarterly revenues are $11.5B, which are larger than Biodexa Pharmaceuticals Plc quarterly revenues of --. GSK Plc's net income of $2.9B is higher than Biodexa Pharmaceuticals Plc's net income of --. Notably, GSK Plc's price-to-earnings ratio is 14.26x while Biodexa Pharmaceuticals Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GSK Plc is 2.45x versus 0.73x for Biodexa Pharmaceuticals Plc. Usually stocks with elevated PS ratios are considered overvalued.

NuCana Plc has a net margin of 25.09% compared to GSK Plc's net margin of --. GSK Plc's return on equity of 42.84% beat NuCana Plc's return on equity of -286.82%.

GSK Plc has a consensus price target of --, signalling downside risk potential of --. On the other hand NuCana Plc has an analysts' consensus of $104.00 which suggests that it could grow by 485881.31%. Given that NuCana Plc has higher upside potential than GSK Plc, analysts believe NuCana Plc is more attractive than GSK Plc.

GSK Plc has a beta of 0.211, which suggesting that the stock is 78.943% less volatile than S&P 500. In comparison NuCana Plc has a beta of 1.595, suggesting its more volatile than the S&P 500 by 59.472%.

GSK Plc has a quarterly dividend of $0.21 per share corresponding to a yield of 3.36%. NuCana Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GSK Plc pays 96.58% of its earnings as a dividend. NuCana Plc pays out -- of its earnings as a dividend. GSK Plc's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

GSK Plc quarterly revenues are $11.5B, which are larger than NuCana Plc quarterly revenues of --. GSK Plc's net income of $2.9B is higher than NuCana Plc's net income of -$378.9K. Notably, GSK Plc's price-to-earnings ratio is 14.26x while NuCana Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GSK Plc is 2.45x versus -- for NuCana Plc. Usually stocks with elevated PS ratios are considered overvalued.

Tiziana Life Sciences Ltd. has a net margin of 25.09% compared to GSK Plc's net margin of --. GSK Plc's return on equity of 42.84% beat Tiziana Life Sciences Ltd.'s return on equity of --.

GSK Plc has a consensus price target of --, signalling downside risk potential of --. On the other hand Tiziana Life Sciences Ltd. has an analysts' consensus of $7.99 which suggests that it could grow by 361.75%. Given that Tiziana Life Sciences Ltd. has higher upside potential than GSK Plc, analysts believe Tiziana Life Sciences Ltd. is more attractive than GSK Plc.

GSK Plc has a beta of 0.211, which suggesting that the stock is 78.943% less volatile than S&P 500. In comparison Tiziana Life Sciences Ltd. has a beta of -0.047, suggesting its less volatile than the S&P 500 by 104.653%.

GSK Plc has a quarterly dividend of $0.21 per share corresponding to a yield of 3.36%. Tiziana Life Sciences Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GSK Plc pays 96.58% of its earnings as a dividend. Tiziana Life Sciences Ltd. pays out -- of its earnings as a dividend. GSK Plc's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

GSK Plc quarterly revenues are $11.5B, which are larger than Tiziana Life Sciences Ltd. quarterly revenues of --. GSK Plc's net income of $2.9B is higher than Tiziana Life Sciences Ltd.'s net income of --. Notably, GSK Plc's price-to-earnings ratio is 14.26x while Tiziana Life Sciences Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GSK Plc is 2.45x versus 2,803.69x for Tiziana Life Sciences Ltd.. Usually stocks with elevated PS ratios are considered overvalued.